跳至主要内容
临床试验/JPRN-UMIN000016728
JPRN-UMIN000016728招募中2 期

Efficacy and safety of nab-paclitaxel plus carboplatin in patients with Carcinoma of unknown primary site - Efficacy and safety of CBDCA plus nab-PTX in patients with CUP

Teikyo University School of Medicine0 个研究点目标入组 30 人开始时间: 2015年3月6日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1)Indication for radical operation and radiotherapy. 2)Patients unable to take nab-paclitaxel and CBDCA because of significant cardiovascular abnormalities, renal dysfunctions, hepatic insufficiency, uncontrolled diabetes, uncontrolled hypertension, bleeding tendency, active interstitial pneumonia,etc. 3)Known active brain metastasis. 4)Acute or subacute idiopathic interstitial pneumonia 5)Patient received a bone-marrow transplantation 6)Patient received a peripheral stem cell transplantation 7)Known hypersensitivity to any drugs 8)Seropositivity for HBsAg 9)Pregnancy or breast feeding.

研究者

发起方
Teikyo University School of Medicine

相似试验

Efficacy and safety of nab-paclitaxel plus... | 临床试验